Literature DB >> 23955799

Implications of Bit1 and AIF overexpressions in esophageal squamous cell carcinoma.

Tianli Fan1, Fang Tian, Shanyong Yi, Yang Ke, Shengna Han, Lirong Zhang, Hongtao Liu.   

Abstract

Overwhelming evidence has demonstrated that Bit1 and AIF as mitochondrial proteins are implicated in the development and progression of a variety of tumors. However, their expressions and biological functions in esophageal squamous cell carcinoma (ESCC) remain to be delineated. In the present study, we found that Bit1, AIF, and Bcl-2 levels in ESCC tissues were significantly higher than those in normal esophageal epithelial tissues and dysplasia tissues (P < 0.05). Stepwise investigation demonstrated that Bit1 and Bcl-2 levels were both tightly associated with lymphatic metastasis and TNM staging (P < 0.05), and the levels of Bit1 mRNA as well as AIF and Bcl-2 proteins were both closely related to tumor differentiation (P < 0.05), but not related to the patients' age and gender (P > 0.05). Importantly, Bit1 mRNA and protein levels in ESCC with lymphatic metastasis and TNM staging in III and IV were markedly higher than that without lymphatic metastasis and TMN staging in I and II. Further analysis showed that expression of Bit1 protein was both positively correlated with expressions of AIF and Bcl-2 proteins (r = 0.408 and 0.405, respectively; P < 0.05). Correctively, our data cited earlier suggest that Bit1 plays pivotal roles in the development and progression of ESCC, and its biological functions in ESCC may be closely associated with AIF and Bcl-2 levels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23955799     DOI: 10.1007/s13277-013-1073-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  41 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  The Bcl-2 family: roles in cell survival and oncogenesis.

Authors:  Suzanne Cory; David C S Huang; Jerry M Adams
Journal:  Oncogene       Date:  2003-11-24       Impact factor: 9.867

Review 3.  Targeting the B-cell lymphoma/leukemia 2 family in cancer.

Authors:  Matthew S Davids; Anthony Letai
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

4.  Expression of AIF and HtrA2/Omi in small lymphocytic lymphoma and diffuse large B-cell lymphoma.

Authors:  Shaoying Li; Mei Wan; Xu Cao; Yongsheng Ren
Journal:  Arch Pathol Lab Med       Date:  2011-07       Impact factor: 5.534

Review 5.  Combined modality therapy in the treatment of esophageal cancer.

Authors:  D H Ilson; D P Kelsen
Journal:  Semin Oncol       Date:  1994-08       Impact factor: 4.929

6.  Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinoma.

Authors:  Céline Bossard; Ivan Bieche; Viviane Le Doussal; Rosette Lidereau; Jean Christophe Sabourin
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

Review 7.  Chemotherapy in esophageal cancer.

Authors:  P C Enzinger; D H Ilson; D P Kelsen
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

Review 8.  Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population (review).

Authors:  Deyin Xing; Wen Tan; Dongxin Lin
Journal:  Oncol Rep       Date:  2003 Sep-Oct       Impact factor: 3.906

9.  Effects of the proapoptotic regulator Bcl-2/adenovirus EIB 19-kDa-interacting protein 3 on the chemosensitivity of human colon cancer cell lines.

Authors:  Zi Wang; Chunmei Huang; Jianshuang Zeng; Qian Deng; Hui Zeng; Zhen Liu; Xingchen Peng; Feng Bi; Qiulin Tang; Zhiping Li
Journal:  Oncol Lett       Date:  2012-09-21       Impact factor: 2.967

10.  Maté consumption and the risk of squamous cell esophageal cancer in uruguay.

Authors:  Vikash Sewram; Eduardo De Stefani; Paul Brennan; Paolo Boffetta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-06       Impact factor: 4.254

View more
  8 in total

1.  AIF promotes a JNK1-mediated cadherin switch independently of respiratory chain stabilization.

Authors:  Andrew J Scott; Sierra A Walker; Joshua J Krank; Amanda S Wilkinson; Kaitlyn M Johnson; Eric M Lewis; John C Wilkinson
Journal:  J Biol Chem       Date:  2018-08-09       Impact factor: 5.157

2.  Bit1-a potential positive regulator of epithelial-mesenchymal transition in lens epithelial cells.

Authors:  Xinhua Wu; Jing Ruan; Bo Ma; Min Luo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-28       Impact factor: 3.117

Review 3.  The structural basis for cancer treatment decisions.

Authors:  Ruth Nussinov; Hyunbum Jang; Chung-Jung Tsai
Journal:  Oncotarget       Date:  2014-09-15

4.  Basal metabolic state governs AIF-dependent growth support in pancreatic cancer cells.

Authors:  Andrew J Scott; Amanda S Wilkinson; John C Wilkinson
Journal:  BMC Cancer       Date:  2016-04-23       Impact factor: 4.430

5.  Bit1 Silencing Enhances the Proliferation, Migration, and Invasion of Glioma Cells Through Activation of the IL-6/STAT3 Pathway.

Authors:  Zhengfeng Wang; Menglei Yin; Ruihua Wang; Xianzhi Liu; Dongming Yan
Journal:  Onco Targets Ther       Date:  2020-03-24       Impact factor: 4.147

Review 6.  PTRH2: an adhesion regulated molecular switch at the nexus of life, death, and differentiation.

Authors:  Austin D Corpuz; Joe W Ramos; Michelle L Matter
Journal:  Cell Death Discov       Date:  2020-11-12

7.  Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK-paxillin pathway.

Authors:  Tianli Fan; Jing Chen; Lirong Zhang; Pan Gao; Yiran Hui; Peirong Xu; Xiaqing Zhang; Hongtao Liu
Journal:  Mol Cancer       Date:  2016-03-08       Impact factor: 27.401

8.  MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway.

Authors:  Wei-Wei Wang; Zhi-Hua Zhao; Li Wang; Pan Li; Kui-Sheng Chen; Jian-Ying Zhang; Wen-Cai Li; Guo-Zhong Jiang; Xiang-Nan Li
Journal:  EBioMedicine       Date:  2019-08-02       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.